Article Text

Download PDFPDF
A new rapid and sensitive assay for detecting the T315I BCR-ABL kinase domain mutation in chronic myeloid leukaemia
  1. J S Khorashad1,
  2. N Thelwell2,
  3. D Milojkovic1,
  4. D Marin1,
  5. J A Watson2,
  6. J M Goldman1,
  7. J F Apperley1,
  8. L Foroni1,
  9. A G Reid1
  1. 1
    Department of Haematology, Imperial College London, London, UK
  2. 2
    DxS Ltd, Manchester, UK
  1. Alistair G Reid, Department of Haematology, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, London W12 0NN, UK; a.reid{at}


A significant minority of chronic myeloid leukaemia patients eventually develop resistance to imatinib, often as a result of point mutations within the BCR-ABL kinase domain. Second-line tyrosine kinase inhibitors (TKIs) are effective against mutations that confer imatinib resistance; however, the T315I BCR-ABL mutant has proved resistant to all available TKIs. An assay facilitating early identification of BCR-ABLT315I would therefore aid in identifying high-risk patients who may benefit from alternative therapy. This report describes the development of a sensitive T315I mutation detection methodology based on real-time PCR with self-probing fluorescent primers. The technique demonstrated complete concordance with direct sequencing, correctly identifying 34 T315I-positive samples from a total of 61 samples screened. In a limiting dilution assay, the mutated clone was detectable to a level of 1% of total cells. The data show that Scorpions PCR enables rapid screening for BCR-ABLT315I in chronic myeloid leukaemia patients and is appropriate for use in a clinical setting.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Competing interests: None.

  • Ethics approval: Ethics approval was granted for this study.